Panacea Biotec bags $127 million order to supply pentavalent vaccine

11 Oct 2022 , 08:36 AM

Panacea Biotec, a manufacturer of vaccines, announced on Monday that UNICEF and the Pan American Health Organization (PAHO) had awarded it a long-term supply contract worth $127.30 million (roughly Rs1,040 crore) for the supply of its WHO pre-qualified fully liquid pentavalent vaccine, Easyfive-TT (DTwP-HepB-Hib).

During the years 2023 through 2027, UNICEF will get a $99 million grant to provide 99.70 million doses, and PAHO will receive a $28.55 million grant to provide 24.83 million doses.

In 2005, Easyfive-TT was introduced in India. Over 150 million doses have been given to more than 75 countries worldwide since getting WHO prequalification in 2008.

EasyFive-TT is a ready-to-use combination vaccine that lowers the overall cost of immunization for all parties involved, decreases the number of visits to vaccination centres, and does not require clinic staff to prepare it.

The vaccination guards kids against Diphtheria, Tetanus, Pertussis, Hepatitis B, and invasive infections brought on by Haemophilus Influenza Type B. These are five terrible diseases.

The United Nations’ Sustainable Development Goals (SDGs) include the goal of lowering the under-five mortality rate to less than 25 per 1000 live births.

For feedback and suggestions, write to us at [e-mail]